Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: Compositions and methods for the treatment of bacterial infections include conjugates containing an Fc domain covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular, conjugates can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

Abstract: Compositions and methods for the treatment of bacterial infections include conjugates containing an Fc domain covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular, conjugates can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral RSV F protein (e.g., Presatovir, MDT 637, JNJ 179, or an analog thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., RSV infections).

Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.

Abstract: A path selection module selects at least two fiber channel paths between a fiber channel host and a fiber channel destination. A trace route module performs one or more fiber channel trace route procedures for each of the at least two fiber channel paths. The trace route module provides a set of fiber channel links between the fiber channel host and the fiber channel destination for each of the at least two fiber channel paths. A record registration module registers with one or more event servers to receive link incident records for the fiber channel links in the sets of fiber channel links.

Abstract: A path selection module selects at least two fibre channel paths between a fibre channel host and a fibre channel destination. A trace route module performs one or more fibre channel trace route procedures for each of the at least two fibre channel paths. The trace route module provides a set of fibre channel links between the fibre channel host and the fibre channel destination for each of the at least two fibre channel paths. A record registration module registers with one or more event servers to receive link incident records for the fibre channel links in the sets of fibre channel links.

Abstract: Techniques for model calibration and alignment of measurement contours of printed layout features with simulation contours obtained with a model are disclosed. With various implementations of the invention, contour point errors are determined. Based on the contour point errors and a cost function, values of alignment parameters may be determined. The values of alignment parameters may be used to realign the measurement contours for model calibration. The alignment may be conducted concurrently with model calibration.

Abstract: The present invention is a method, apparatus and program storage device for providing data path optimization for redundant data paths. The present invention provides data path optimization that increases the data access throughput and availability to a device by using multiple paths when a modification event occurs.

Abstract: The present invention is a method, apparatus and program storage device for providing data path optimization for redundant data paths. The present invention provides data path optimization that increases the data access throughput and availability to a device by using multiple paths when a modification event occurs.

Abstract: The present invention is a method, apparatus and program storage device for providing data path optimization for redundant data paths. The present invention provides data path optimization that increases the data access throughput and availability to a device by using multiple paths when a modification event occurs.

Abstract: An apparatus, system, and method are disclosed for communicating over multiple paths. A reserve interception module intercepts a single-path reserve command from a host. The host-computing environment is configured to issue single-path commands, but is not configured to issue multiple-path commands. A reserve generation module generates a multiple-path reserve command in response to the single-path command. A reserve command module reserves multiple paths between the host and the storage device using the multiple-path command, enabling the host to communicate over multiple paths with the storage device.